Search research articles
Contact Us
Filters
Showing results (1-10 of 8) with videos related to
Page
of 1
Sort By:
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
January 14, 2009
Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice
Haruhiko Sugino, Takashi Futamura, Yasuhide Mitsumoto, et al.
Neuroscience Research
|
November 4, 2008
Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice
Akiko Muroyama, Makiko Inaka, Hiroaki Matsushima, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
June 22, 2010
Aripiprazole attenuates established behavioral sensitization induced by methamphetamine
Takashi Futamura, Satoshi Akiyama, Haruhiko Sugino, et al.
Clinical Therapeutics
|
August 6, 2015
Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success
Haruhiko Sugino, Akihito Watanabe, Naoki Amada, et al.
Neuropsychopharmacology Reports
|
September 6, 2019
Brexpiprazole has a low risk of dopamine D<sub>2</sub> receptor sensitization and inhibits rebound phenomena related to D<sub>2</sub> and serotonin 5-HT<sub>2A</sub> receptors in rats
Naoki Amada, Hitomi Akazawa, Yuta Ohgi, et al.
Journal of Pharmacological Sciences
|
March 8, 2007
Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine
Kenji Maeda, Haruhiko Sugino, Tsuyoshi Hirose, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 21, 2014
Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator
Kenji Maeda, Linda Lerdrup, Haruhiko Sugino, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 21, 2014
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Kenji Maeda, Haruhiko Sugino, Hitomi Akazawa, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 8) with videos related to
Sort By:
Page
of 1
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
January 14, 2009
Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice
Haruhiko Sugino, Takashi Futamura, Yasuhide Mitsumoto, et al.
Neuroscience Research
|
November 4, 2008
Enhanced susceptibility to MPTP neurotoxicity in magnesium-deficient C57BL/6N mice
Akiko Muroyama, Makiko Inaka, Hiroaki Matsushima, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry
|
June 22, 2010
Aripiprazole attenuates established behavioral sensitization induced by methamphetamine
Takashi Futamura, Satoshi Akiyama, Haruhiko Sugino, et al.
Clinical Therapeutics
|
August 6, 2015
Global Trends in Alzheimer Disease Clinical Development: Increasing the Probability of Success
Haruhiko Sugino, Akihito Watanabe, Naoki Amada, et al.
Neuropsychopharmacology Reports
|
September 6, 2019
Brexpiprazole has a low risk of dopamine D<sub>2</sub> receptor sensitization and inhibits rebound phenomena related to D<sub>2</sub> and serotonin 5-HT<sub>2A</sub> receptors in rats
Naoki Amada, Hitomi Akazawa, Yuta Ohgi, et al.
Journal of Pharmacological Sciences
|
March 8, 2007
Clozapine prevents a decrease in neurogenesis in mice repeatedly treated with phencyclidine
Kenji Maeda, Haruhiko Sugino, Tsuyoshi Hirose, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 21, 2014
Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator
Kenji Maeda, Linda Lerdrup, Haruhiko Sugino, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
June 21, 2014
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator
Kenji Maeda, Haruhiko Sugino, Hitomi Akazawa, et al.
Page
of 1